Table 5.

Analytical sensitivity against HBV subtypes “ad” and “ay”

Subtype panel (PHA807)	Lumipulse HBsAg‐HQ	Architect HBsAg QT	HISCL HBsAg	Lumipulse HBsAg	ADVIA Centaur HBsAg II
PHA‐01 ad (3.1 ng/mL)	+	+	+	+	+
PHA‐02 ad (1.5 ng/mL)	+	+	+	+	+
PHA‐03 ad (1.0 ng/mL)	+	+	+	+	+
PHA‐04 ad (0.9 ng/mL)	+	+	+	+	+
PHA‐05 ad (0.7 ng/mL)	+	+	+	+	+
PHA‐06 ad (0.5 ng/mL)	+	+	+	+	+
PHA‐07 ad (0.4 ng/mL)	+	+	+	+	+
PHA‐08 ad (0.3 ng/mL)	+	+	+	+	+
PHA‐09 ad (0.2 ng/mL)	+	+	+	−	+
PHA‐10 ad (0.1 ng/mL)	+	−	−	−	−
PHA‐10 × 2 dil. (0.05 ng/mL)	+	−	−	−	−
PHA‐10 × 4 dil. (0.025 ng/mL)	+	−	−	−	−
PHA‐11 ay (2.6 ng/mL)	+	+	+	+	+
PHA‐12 ay (1.3 ng/mL)	+	+	+	+	+
PHA‐13 ay (0.9 ng/mL)	+	+	+	+	+
PHA‐14 ay (0.8 ng/mL)	+	+	+	+	+
PHA‐15 ay (0.6 ng/mL)	+	+	+	+	+
PHA‐16 ay (0.5 ng/mL)	+	+	+	+	+
PHA‐17 ay (0.4 ng/mL)	+	+	+	+	+
PHA‐18 ay (0.3 ng/mL)	+	+	+	−	+
PHA‐19 ay (0.2 ng/mL)	+	+	+	−	+
PHA‐20 ay (0.1 ng/mL)	+	−	−	−	−
PHA‐20 × 2 dil. (0.05 ng/mL)	+	−	−	−	−
PHA‐20 × 4 dil. (0.025 ng/mL)	+	−	−	−	−

The sample judged as positive was described as +, and the specimen judged as negative was done as –.